Express News | Watching Legend Biotech; Traders Circulate Unconfirmed Rumor Suggesting The Co Received Takeover Interest And Hired Centerview Partners To Help Review The Offer
Legend Biotech Surges Amid Takeover Speculation
Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Buy Rating Affirmed for Legend Biotech Amid Promising Carvykti Trial Results and Expert Endorsements
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Genscript Biotech's Phase 3 Multiple Myeloma Drug Trial Yields Positive Results
Genscript Biotech's (HKG:1548) subsidiary, Legend Biotech, said a phase 3 trial of Carvykti in multiple myeloma yielded "statistically significant and clinically meaningful" overall survival results,
Legend Biotech Is Maintained at Outperform by BMO Capital
Legend Biotech Is Maintained at Outperform by BMO Capital
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright analyst Mitchell Kapoor maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $73.According to TipRanks data, the analyst has a success rate of 31.7%
BMO Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $90
BMO Capital analyst Kostas Biliouris maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 39.3% an
Scotiabank Keeps Their Buy Rating on Legend Biotech (LEGN)
Buy Rating on Legend Biotech: CARVYKTI's Clinical Success and Expanding Manufacturing Capacity
Express News | HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target
Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.
According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.
Genscript Bio (01548): Legend Biotech announced positive overall survival results for the key CARTITUDE-4 Phase III trial for the treatment of multiple myeloma.
Genscript Bio (01548) announced that Legend Biotech (NASDAQ: LEGN) plans to list on a US stock exchange.
Legend Biotech's CARVYKTI Triumphs in Phase 3 Trial
Express News | Legend Biotech Corp - Safety Results Were Consistent With Established Safety Profile of Carvykti(®), and No New Safety Signals Were Identified
Express News | Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 Cartitude-4 Trial in Multiple Myeloma
Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Scotiabank Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
Scotiabank analyst George Farmer maintains $Legend Biotech(LEGN.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 46.1% and a